Prescription Drug Monitoring Program

Slides:



Advertisements
Similar presentations
Opioid Update F ederation of S tate M edical B oards Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain July 2013 F ederation.
Advertisements

“Medication Units” (Opioid Treatment Programs) Drug Enforcement Administration James “Jim” Arnold Chief, Policy Unit Office of Diversion Control D E A.
Preventing Prescription Drug Abuse: Laws and Legislation Hollie Hendrikson, MSc Policy Specialist, Health Program.
Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Board Meeting April 8, 2015.
Controlling Off-Label Narcotics Usage - Impact of New Arizona Legislation ARS §
VIRGINIA PRESCRIPTION MONITORING PROGRAM C.A.R.E Presentation February 27, 2015 Ralph Orr Director, Virginia Prescription Monitoring Program.
Slide 1 Best Practices Working Group Chapter 244 Acts of 2012 Joint Policy Working Group Bureau of Health Care Safety and Quality Director Madeleine Biondolillo,
Prescription Drug Monitoring Programs: Analysis of State Level Usage Requirements Matthew Penn, JD, Carla Chen, JD Director, Public Health Law Program.
The Prescription Behavior Surveillance System: Applications of De-identified PDMP Data in Public Health Surveillance Rx Abuse Summit April 23, 2014 Peter.
Responsibilities and Principles of Drug Administration
Opioid Use in Work-related Injuries Pacific Northwest Chapter - Association of Occupational Health Professionals (AOHP) January 4, 2011 Jaymie Mai, PharmD.
For Pain or Not for Pain: Methadone Madness
Maine Prescription Monitoring Program Using the PMP to Improve Patient Care John Lipovsky, MPPM, AREM, PMM Prescription Monitoring Program Coordinator.
Texas State Board of Medical Examiners Bruce A. Levy, M.D., J.D.
Buprenorphine Treatment for Opioid Dependence CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for.
Ensuring Availability and Preventing Diversion International Pain Policy Fellowship August 7, 2012 David E. Joranson University of Wisconsin Pain & Policy.
Tom Waddell Urban Health Clinic: Patients Using Controlled Medicines* If you are taking controlled medicines, your safety is our highest priority! Our.
John Lipovsky, MPPM, AREM, PMM
TNSAM Addiction Medicine. Data source: Tennessee Department of Health, Office of Health Statistics, Death Statistical System. Overdose deaths were defined.
Maine Prescription Monitoring Program Using the PMP to Improve Patient Care John Lipovsky, MPPM, AREM, PMM Prescription Monitoring Program Coordinator.
Georgia’s New and Improved PDMP. Greg Reybold, J.D. VP Public Policy & Association Counsel Georgia Pharmacy Association.
Maine Prescription Monitoring Program Using the PMP to Improve Patient Care John Lipovsky, MPPM, AREM, PMM Prescription Monitoring Program Coordinator.
ASTHO Prescription Drug Misuse and Abuse Strategic Map:
SCRIPTS South Carolina Reporting & Identification Prescription Tracking System.
Denis G. Patterson, DO ECHO Project April 20, 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain.
Prepared by Dr. Ramin Safakish, MD, FRCPC – March 2016.
Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Pennsylvania's Prescription Drug Monitoring Program (PDMP) May 17, 2016.
ABC-MAP Act 191 of 2014 September 16, 2016 Pennsylvania’s Prescription Drug Monitoring Program (PA PDMP)
CDC Guideline for Prescribing Opioids for Chronic Pain- United States-2016 Gisele J. Girault, M.D. First Choice Healthcare Columbia, SC.
Oregon Prescription Drug Monitoring Program
Incidental Medical Services (IMS) Department of
Medication Assisted Treatment
Comparison of Opioid Prescribing Guidelines Violations by Clinical Speciality Chia-Chen Teng1,2, Christy Porusnik3, Erin Johnson4, Robert Rolfs3, Jonathan.
Current Concepts in Pain Management
OPIOID EPIDEMIC.
Wireless Access SSID: cwag2017
*Risk Evaluation and Mitigation Strategy
Cover slide.
Nebraska Prescription Drug Overdose Prevention Program Efforts
Medication-Assisted Therapy at Coleman Profession Services
Opioids – A Pharmaceutical Perspective on Prescription Drugs
An Overview of the ePDMP
ROOM project Addressing the Opioid Epidemic in the U.P.
Opioid Prescribing & Monitoring
Health Home Program Services
Prescribing Opioids in Vermont
Complete a legally valid prescription.
Controlled substance compliance
Medication order entry & Fill process
Controlled Substance Monitoring & Legislative updates
Differentiating Drug-Seeking Behavior From Poorly Controlled Pain
Barbara Allison-Bryan, MD
PRESCRIPTION MONITORING PROGRAMS
Lessons Learned In Opioid Treatment From the Pain Action Consulting Team.
Opiate Roundtable March 29, 2018 Karen Burgess, MD
Review why we’re doing this work Display survey results
Prescription Drug Monitoring Program
Prescription Drug Monitoring Program
Statewide Health Home Initiatives
Safe and Appropriate Use of Opiates
Prescription Drug Monitoring Program
2019 Medicare Part D Rule Opioid-related Provisions
National Credentialing Forum 2019 San Diego, CA February
Illinois Prescription Monitoring Program
Calculating and Using Morphine Equivalent Doses of Opioids
S. Paul Edwards, General Counsel
Dr. Mark Levine, Commissioner of Health
Situation analysis in Kyrgyzstan
Pain Management JEFFREY TAN HO, D.O.
Presentation transcript:

Prescription Drug Monitoring Program Joshua Lee PharmD Alabama Community Care March 29, 2018

Prescription Drug Monitoring Program (PDMP) Established and maintained by the Alabama Department of Public Health (ADPH) Purposes: Promote health and welfare of the public Detect diversion, misuse, and abuse of prescription controlled substances Reporting: Became mandatory in April 2006 For anyone who dispenses Controlled Substances Class II-V

Goals of the PDMP Goals: “To provide a source of information for practitioners and pharmacists regarding the controlled substance usage of a patient; To reduce prescription drug abuse by providers and patients; To reduce time and effort to explore leads and assess the merits of possible drug diversion cases; and To educate physicians, pharmacists, policy makers, law enforcement, and the public regarding the diversion, abuse, and misuse of controlled substances.” Resource: http://www.alabamapublichealth.gov/PDMP/index.html

PDMP Information The PDMP is NOT linked to insurance companies The PDMP is NOT “real time.” It has a two week disclaimer yet much of the information is loaded within days of dispensing. If you can’t locate your patient in the PDMP search then please note that the patient may use a different name or different spelling with the dispensing location. The PDMP does not “track” the usage of controlled substances by consumers. It is a database and licensed professionals with access can utilize it for controlled substance history.

PDMP Legal Obligations Please refer to the Code of Alabama (see Title 20, Section 20-2-214). "A licensed practitioner approved by the department who has authority to prescribe, dispense, or administer controlled substances, provided, however, that such access shall be limited to information concerning a current or prospective patient of the practitioner." "Practitioners shall have no requirement or obligation to access or check the information in the controlled substances database prior to prescribing, dispensing, or administering medications or as part of their professional practice." "A licensed pharmacist approved by the department, provided, however, that such access is limited to information related to the patient or prescribing practitioner designated on a controlled substance prescription that a pharmacist has been asked to fill. Pharmacists shall have no requirement or obligation to access or check the information in the controlled substances database prior to dispensing or administering medications or as part of their professional practices." Resource: http://www.alabamapublichealth.gov/PDMP/index.html

Alabama State Board of Medical Examiners (ALBME) Rules and Regulations 540-X-4-.09 Risk and Abuse Mitigation Strategies by Prescribing Physicians Adverse events are more likely to occur at increasing controlled substance pain medication dosages Higher risk for overdose and death The standard for calculating opioid dosages is the Morphine Milligram Equivalency (as set forth by the CDC).

Calculating MME Conversion Factor Chart: Determine the total daily amount of each opioid that the patient takes Convert the daily amount into MME’s Dose X Conversion Factor= MME Add them together PRECAUTIONS: Methadone conversion factor varies Fentanyl is in mcg/hour NOT mg/day MME’s are not intended to be utilized for switching between opioids Dose conversions are estimates. They do NOT account for variations in individual genetics and pharmacokinetics. Resource: https://www.cdc.gov/drugoverdose/ pdf/calculating_total_daily_dose- a.pdf OPIOID (mg/day except where specified) Conversion Factor Codeine 0.15 Fentanyl transdermal (in mcg/hr) 2.4 Hydrocodone 1 Hydromorphone 4 Methadone 1-20 mg/day 21-40 mg/day 8 41-60 mg/day 10 > 61-80 mg/day 12 Morphine Oxycodone 1.5 Oxymorphone 3

ALBME Opinion on Risk and Abuse Mitigation Strategies Will vary from patient to patient Examples: “(a) Pill counts; (b) Urine drug screening; (c) PDMP checks; (d) Consideration of abuse-deterrent medications; (e) Monitoring the patient for aberrant behavior; (f) Providing a patient with opiate risk education prior to prescribing controlled substances; and (g) Using validated risk-assessment tools, examples of which shall be maintained by the Board.” Resource: http://www.albme.org/riskabusemit.html

ALBME Requirements for Utilizing the PDMP “(a) For controlled substance prescriptions totaling 30 MME or less per day, physicians are expected to use the PDMP in a manner consistent with good clinical practice. (b) When prescribing a patient controlled substances of more than 30 MME per day, physicians shall review that patient's prescribing history through the PDMP at least two (2) times per year, and each physician is responsible for documenting the use of risk and abuse mitigation strategies in the patient’s medical record. (c) Physicians shall query the PDMP to review a patient's prescribing history every time a prescription for more than 90 MME per day is written, on the same day the prescription is written.” Resource: http://www.albme.org/riskabusemit.html

ALBME PDMP Exemptions “(a) Nursing home patients; (b) Hospice patients, where the prescription indicates hospice on the physical prescription;  (c) When treating a patient for active, malignant pain; or (d) Intra-operative patient care.” Resource: http://www.albme.org/riskabusemit.html

ALBME Continued Reconsider benzodiazepine and opioid combination. Consider alternative forms of treatment. Beginning 1/1/2018 each holder of an Alabama Controlled Substance Certificate shall acquire 2 credits of CME in controlled substance prescribing every two years. Physicians are expected to use risk and abuse mitigation strategies when prescribing ANY controlled substance. Physicians should use extreme caution when prescribing multiple controlled substance medications. “A violation of this rule is grounds for the suspension, restriction, or revocation of a physician's Alabama Controlled Substances Certificate or license to practice medicine.” Resource: http://www.albme.org/riskabusemit.html